MorphoSys AG
Other OTCTotal Valuation
MorphoSys AG carries a market capitalization of 2.76B, placing it among publicly traded companies globally. Its enterprise value stands at 1.22B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.76B |
| Enterprise Value | 1.22B |
Share Statistics
MorphoSys AG currently has 37.60M shares outstanding.
| Shares Outstanding | 37.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
MorphoSys AG trades at a trailing price-to-earnings ratio of 15.61. The price-to-sales ratio is 5.32, and the price-to-book ratio stands at -1.30.
| PE Ratio | 15.61 |
| PS Ratio | 5.32 |
| PB Ratio | -1.30 |
| P/TBV Ratio | -1.12 |
| P/FCF Ratio | -6.45 |
| P/OCF Ratio | -6.44 |
Enterprise Valuation
| EV / Sales | 5.13 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
MorphoSys AG maintains a current ratio of 3.08, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1,296.52, indicating moderate leverage, while an interest coverage ratio of -1.85 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.08 |
| Quick Ratio | 2.74 |
| Debt / Equity | 1,296.52 |
| Debt / EBITDA | -2.60 |
| Interest Coverage | -1.85 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -8.58 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.35 |
Taxes
| Income Tax | -1.19M |
| Effective Tax Rate | N/A |
Stock Price Statistics
MorphoSys AG's stock has gained approximately 107.97616% over the past 52 weeks. The 50-day moving average sits at 73.27, while the 200-day moving average is 72.22.
| Beta (5Y) | N/A |
| 52-Week Price Change | 107.97616% |
| 50-Day Moving Average | 73.27 |
| 200-Day Moving Average | 72.22 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, MorphoSys AG generated 238.36M in revenue and converted that into -189.73M in net income, yielding earnings per share of -5.55. EBITDA reached -245.06M, while operating income came in at -250.80M.
| Revenue | 238.36M |
| Gross Profit | 179.92M |
| Operating Income | -250.80M |
| Pretax Income | -189.21M |
| Net Income | -189.73M |
| EBITDA | -245.06M |
| EBIT | -250.80M |
| Earnings Per Share (EPS) | -5.55 |
Balance Sheet
MorphoSys AG holds 682.76M in cash and equivalents against 635.93M in total debt, resulting in a net debt position of 465.01M. Total book value stands at -975.48M, with working capital of 549.71M providing operational flexibility.
| Cash & Cash Equivalents | 682.76M |
| Total Debt | 635.93M |
| Net Debt | 465.01M |
| Equity (Book Value) | -975.48M |
| Book Value Per Share | -28.55 |
| Working Capital | 549.71M |
Cash Flow
MorphoSys AG produced -197.20M in operating cash flow over the past twelve months. After subtracting -526,221.00 in capital expenditures, free cash flow totaled -197.73M - equivalent to -5.79 per share.
| Operating Cash Flow | -197.20M |
| Capital Expenditures | -526,221.00 |
| Free Cash Flow | -197.73M |
| FCF Per Share | -5.79 |
Margins
MorphoSys AG operates with a gross margin of 75.52, reflecting its pricing power and cost economics. The operating margin of -105.22 and net profit margin of -79.60 provide insight into operational efficiency.
| Gross Margin | 75.52 |
| Operating Margin | -105.22 |
| Pretax Margin | -79.38 |
| Profit Margin | -79.60 |
| EBITDA Margin | -102.81 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 3.94 |
| FCF Yield | -15.50 |
Scores
MorphoSys AG posts an Altman Z-Score of -1.22, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.22 |